First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC

BACKGROUND: Limited data exist on outcomes for metastatic renal cell carcinoma (mRCC) patients treated with multiple lines of therapy. Benchmarks for survival are required for patient counselling and clinical trial design. METHODS: Outcomes of mRCC patients from the International mRCC Database Conso...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Ko, J J, Choueiri, T K, Rini, B I, Lee, J-L, Kroeger, N, Srinivas, S, Harshman, L C, Knox, J J, Bjarnason, G A, MacKenzie, M J, Wood, L, Vaishampayan, U N, Agarwal, N, Pal, S K, Tan, M-H, Rha, S Y, Yuasa, T, Donskov, F, Bamias, A, Heng, D Y C
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2014
Soggetti:
Clinical Study
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3992507/
https://ncbi.nlm.nih.gov/pubmed/24691425
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2014.25
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi